Transposon Therapeutics received an undisclosed investment to develop nucleoside inhibitors for neurodegenerative and aging-related diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), all rare and debilitating neurological disorders.
